Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC.
The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 291 |
| CEO | Elizabeth Barrett |
Contact Details
Address: 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540 United States | |
| Phone | 646 768 9780 |
| Website | urogen.com |
Stock Details
| Ticker Symbol | URGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668243 |
| CUSIP Number | M96088105 |
| ISIN Number | IL0011407140 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer and Director |
| Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Vincent I. Perrone | Senior Director of Investor Relations |
| Bryon Wornson | Executive Vice President of Talent, Advocacy and Communications |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research and Development and Technical Operations |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| James Ottinger R.ph. | Executive Vice President of Regulatory Affairs and Quality |
| David Lin | Chief Commercial Officer |
| Timothy Simon | Senior Vice President of Business Development and Portfolio Strategy |
| Ron Bentsur M.B.A. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 10-K | Annual Report |
| Mar 2, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 3, 2026 | 144 | Filing |
| Nov 19, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |